CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--BIOVECTRA Inc., a forward-thinking global contract development and manufacturing organization, today launched a new logo and brand to align with the growing company’s full suite of expertise and core values. “Over the last few years, we have grown significantly in size and added new capabilities, like our fully-operational large-scale biomanufacturing facility in Windsor, Nova Scotia,” said BIOVECTRA Chief Executive Officer, Oliver Technow. “Our modern logo strikes a balance between our biologics offerings and our roots in complex chemistry. Our new brand is inspired by what truly sets us apart – the irrefutable cultural value of care that goes into every detail of every project.”
Driven by the launch of the company’s new website, BIOVECTRA’s new brand is built on three pillars of care: the needs of patients, progressive manufacturing science, and the highly skilled and dedicated team that makes it all happen. “Together with our partners, solving complex manufacturing problems to meet the needs of patients is our mission,” said Technow. “Caring deeply about client programs is, and always has been, our nature.” For over 50 years, BIOVECTRA’s high quality active pharmaceutical ingredients (APIs) have been used in therapeutics to treat cancer, kidney disease, cardiovascular disease, multiple sclerosis, and many other serious illnesses. With the addition of biologics capabilities, the company’s ability to help even more patients has been amplified by entering a field where therapies are advancing rapidly and changing the way health care is delivered.
In addition to adding new capabilities, BIOVECTRA has also bolstered their capacity and enhanced their range of scale through the recent completion of expansion projects on both Prince Edward Island and in Nova Scotia. “In Charlottetown we have added over 60,000 square feet to our API manufacturing capacity footprint, invested in multi-reactor systems to enable higher throughputs, and fortified our large-scale synthetic chemistry and analytical development capabilities,” said BIOVECTRA Chief Commercial Officer, Heather Delage. “Similarly, in Windsor our completed expansion projects have focused on increasing capacity for biologics development, clinical manufacturing, and large-scale commercial manufacturing up to 17,000L.” To further propel the company towards being a top-tier player in biologics, BIOVECTRA intends to add an additional single-use clinical scale suite (100-1000L) to their Windsor operations – slated to be available in early 2022.
The dedicated BIOVECTRA team of relentless problem solvers approach every project like it is their own. From responsive and open project management to experienced process development and engineering, BIOVECTRA’s team of 500+ highly skilled professionals infuse authentic care into everything they do. “Culturally, Atlantic Canadians care for each other and our picturesque communities very naturally,” said Delage. “However, when we say team, we truly include our global partners. We want our partners to feel like they are part of BIOVECTRA, and us part of their journey towards improving the lives of patients.”
Well positioned to serve North American development entities from their five GMP facilities, BIOVECTRA looks forward to continued growth under H.I.G. Capital. With expertise in both microbial fermentation and chemical synthesis, the company is well positioned to tackle today’s development pipeline of increasingly complex molecules.
